H.C. Wainwright analyst Robert Burns downgraded Fate Therapeutics (FATE) to Neutral from Buy with a price target of $7, down from $115, following the termination of the Johnson & Johnson (J&J) collaboration agreement and discontinuation of numerous clinical-stage programs. The analyst downgraded the shares after factoring in the workforce reduction and multiple trial program discontinuations.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FATE:
- Fly Insider: Coinbase, Buckle among week’s notable insider trades
- Fate Therapeutics price target lowered to $16 from $42 at Canaccord
- Citi sees opportunity in Fate Therapeutics shares with ‘damage done’
- Short Report: Bad News Bears continue to claw Silvergate, Futu Holdings
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
